Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM45OJN)

• Drug Name: Mometasone Drug Info
• Synonyms: Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
• Therapeutic Class: Antiinflammatory Agents
• Cross-matching ID:
  PubChem CID: 441335
  ChEBI ID: CHEMBL1201404
  CAS Number: CAS 105102-22-5
  TTD Drug ID: D03HYX
  INTEDE Drug ID: DR1107

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Endometrial cancer	1.96	1.32e-2	56/58 (96.55%)	GADD45B;FOXO3;CDH1;...
Complement and coagulation cascades	1.94	1.32e-2	76/85 (89.41%)	F13A1;SERPING1;CFD;...
Protein digestion and absorption	1.94	2.20e-2	78/103 (75.73%)	COL11A1;COL4A5;SLC38A2;...
Mineral absorption	1.91	2.64e-2	48/60 (80%)	MT1X;MT1G;MT1H;...
Aldosterone-regulated sodium reabsorption	1.78	4.22e-2	34/37 (91.89%)	INSR;PIK3R1;HSD11B2;...
Small cell lung cancer	1.76	3.95e-2	90/92 (97.83%)	GADD45B;NFKBIA;COL4A5;...
Chagas disease	1.75	3.58e-2	93/102 (91.18%)	NFKBIA;C1QA;C1QB;...
DNA replication	-1.81	1.45e-2	34/36 (94.44%)	RFC3;MCM7;POLE2;...
Autoimmune thyroid disease	-1.86	3.63e-3	46/53 (86.79%)	IFNA4;IFNA14;TSHB;...
Type I diabetes mellitus	-1.99	0.00e+0	38/43 (88.37%)	HLA-F;HLA-DQB1;TNF;...
Allograft rejection	-2.06	0.00e+0	32/38 (84.21%)	HLA-G;HLA-F;HLA-DQB1;...
Graft-versus-host disease	-2.08	0.00e+0	32/42 (76.19%)	HLA-G;HLA-F;HLA-DQB1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	4uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼